drugset / Trial / NCT03756883

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

NCT03756883

Phase 3 Completed 999 enrolled Actavis Inc. Teva Pharmaceuticals USA · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, multiple-dose, blinded, placebo-controlled, parallel-group, multiple-center bioequivalence study with pharmacodynamic endpoints

Timeline

Start
2018-12-03
Primary completion
2019-10-26
Completion
2019-11-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified 100 ug Inhaled
Comparator Salmeterol Other / unclassified 50 ug Inhaled

Indications